mutated Ligand Binding Site gene DataBase





About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for EIF2AK2
Gene summary
Basic gene Info.Gene symbolEIF2AK2
Gene nameeukaryotic translation initiation factor 2-alpha kinase 2
CytomapUCSC genome browser: 2p22-p21
Type of geneprotein-coding
DescriptionP1/eIF-2A protein kinasedouble stranded RNA activated protein kinaseeIF-2A protein kinase 2interferon-induced, double-stranded RNA-activated protein kinaseinterferon-inducible elF2alpha kinasep68 kinaseprotein kinase, interferon-inducible double str
Modification date20141207
dbXrefs MIM : 176871
Ensembl : ENSG00000055332
HPRD : 01468
ProteinUniProt: P19525
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_EIF2AK2
BioGPS: 5610
PathwayNCI Pathway Interaction Database: EIF2AK2
Pathway Commons: EIF2AK2
ContextiHOP: EIF2AK2
ligand binding site mutation search in PubMed: EIF2AK2
UCL Cancer Institute: EIF2AK2
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO:0006468protein phosphorylation19189853
GO:0017148negative regulation of translation12882984
GO:0035455response to interferon-alpha19840259
GO:0046777protein autophosphorylation22801494
GO:0051092positive regulation of NF-kappaB transcription factor activity15121867

Ligand binding site mutations for EIF2AK2

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.

Protein structure related information for EIF2AK2
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for EIF2AK2 from PDB

Differential gene expression and gene-gene network for EIF2AK2
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of EIF2AK2 and the right PPI network was created from samples without mutations in the LBS of EIF2AK2. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Phenotype information for EIF2AK2
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type
umls:C0021400Influenza, Human3Biomarker
umls:C0033578Prostatic Neoplasms1Biomarker
umls:C0038220Status Epilepticus1Biomarker

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Pharmacological information for EIF2AK2
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of EIF2AK2 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
ANPAMP-PNP2a19BK296 M366

Conservation information for LBS of EIF2AK2
Multiple alignments for P19525 in multiple species
LBSAA sequence# speciesSpecies
C369IQMEFCDKGTL3Homo sapiens, Mus musculus, Rattus norvegicus
D414GLIHRDLKPGN2Mus musculus, Rattus norvegicus
D414KLIHRDLKPSN1Homo sapiens
D432HIKIGDFGLAT2Mus musculus, Rattus norvegicus
D432QVKIGDFGLVT1Homo sapiens
E367LFIQMEFCDKG3Homo sapiens, Mus musculus, Rattus norvegicus
F368FIQMEFCDKGT3Homo sapiens, Mus musculus, Rattus norvegicus
F421KPSNIFLVDTK1Homo sapiens
F421KPGNIFLVDER1Mus musculus
F421KPGNIFLVDEK1Rattus norvegicus
G274EIELIGSGGFG1Homo sapiens
G274DIEEIGLGGFG1Mus musculus
G274DIEEIGSGGFG1Rattus norvegicus
I273KEIELIGSGGF1Homo sapiens
I273EDIEEIGLGGF1Mus musculus
I273EDIEEIGSGGF1Rattus norvegicus
K296KTYVIKRVKYN1Homo sapiens
K296KRYAIKRVKYN1Mus musculus
K296KTYAIKRITYN1Rattus norvegicus
M366CLFIQMEFCDK3Homo sapiens, Mus musculus, Rattus norvegicus
N419DLKPGNIFLVD2Mus musculus, Rattus norvegicus
N419DLKPSNIFLVD1Homo sapiens
S418RDLKPGNIFLV2Mus musculus, Rattus norvegicus
S418RDLKPSNIFLV1Homo sapiens
V281GGFGQVFKAKH3Homo sapiens, Mus musculus, Rattus norvegicus
V294DGKTYVIKRVK1Homo sapiens
V294DGKRYAIKRVK1Mus musculus
V294DGKTYAIKRIT1Rattus norvegicus

Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas